AzurRx BioPharma’s (NASDAQ:AZRX) quiet period will end on Monday, November 21st. AzurRx BioPharma had issued 960,000 shares in its public offering on October 11th. The total size of the offering was $5,280,000 based on an initial share price of $5.50. During AzurRx BioPharma’s quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Shares of AzurRx BioPharma (NASDAQ:AZRX) opened at 4.542 on Monday. AzurRx BioPharma has a 12-month low of $3.98 and a 12-month high of $5.60. The company’s market cap is $27.38 million. The stock’s 50 day moving average price is $4.63 and its 200-day moving average price is $4.63.

AzurRx BioPharma Company Profile

Azurrx Biopharma, Inc is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The Company’s product pipeline consists of approximately two therapeutic proteins, such as MS1819, which is an autologous (from the same organism) yeast recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis (CP) and cystic fibrosis (CF) patients, and AZX1101, which is a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics, as well as prevention of antibiotic-associated diarrhea (AAD).

5 Day Chart for NASDAQ:AZRX

Receive News & Stock Ratings for AzurRx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma Inc and related stocks with our FREE daily email newsletter.